# CJC-1295 Side Effects Observed in Research

> CJC-1295 side effects documented in the Teichman 2006 human trial include injection-site erythema (~23%), transient flushing and dizziness (~22%), and headache at higher doses. This page reviews the complete adverse-event record and FDA immunogenicity concerns.

## Reported Adverse Effects

CJC-1295 side effects documented in the Teichman 2006 ascending-dose human trial were mild. At doses of 30–125 μg/kg SC:

- Injection-site erythema: ~23% of participants
- Transient flushing and dizziness: ~22%
- Headache: reported at higher dose levels
- No serious adverse reactions at any dose level

Tolerability was best at 30–60 μg/kg [13]. The trial's adverse-event profile should be read in context: n=24 healthy adults, maximum 49 days duration. Long-term (>3 months) human safety data for CJC-1295 does not exist [16].

## Water Retention and Fluid-Related Effects

Fluid retention is among the most consistently reported effects in clinical use reports. The mechanism is GH-stimulated sodium reabsorption in the distal nephron, which prevents pressure natriuresis and increases extracellular volume [8]. This is a direct GH effect observed across the GH-axis stimulation literature. Severity correlates with dose and is typically transient in rodent wash-out studies.

## Axis Suppression: Does CJC-1295 Affect Natural GH Output?

Unlike exogenous GH, CJC-1295 stimulates the pituitary's own production. The Ionescu and Frohman 2006 study confirmed that endogenous GH pulsatility is preserved — pulse frequency and amplitude remained intact [2]. Post-study GH suppression was not reported in the Teichman 2006 28-day or 49-day follow-up periods [18].

## Stack-Specific Adverse Effects

The stacked CJC-1295 + ipamorelin combination amplifies GH pulse magnitude via dual-pathway stimulation. Documented downsides include more pronounced water retention and flushing than either peptide alone [13]. No published human RCT has characterized adverse events specifically for the combined regimen.

## CNS Effects: Sleep and Stimulation

Community reports note vivid dreams and transient sleep disruption when the no-DAC form is dosed close to bedtime, attributed to the GH pulse coinciding with sleep onset. Systematic sleep architecture studies for CJC-1295 no DAC are absent from the peer-reviewed literature.

## FDA Regulatory Safety Assessment

CJC-1295 is not FDA-approved for any indication. The FDA PCAC reviewed CJC-1295 in December 2024 for potential 503A bulk-drug compounding inclusion (docket FDA-2024-N-4777). The FDA identified potential immunogenicity concerns related to aggregation and peptide-related impurities in compounded injectable formulations [16]. WADA prohibits CJC-1295 under the 2024 Prohibited List, Section S2.

## References

[2] Ionescu M, Frohman LA. J Clin Endocrinol Metab. 2006;91(12):4792-7. https://pubmed.ncbi.nlm.nih.gov/17018654/
[8] Johannsson G, et al. J Clin Endocrinol Metab. 2002;87(4):1743-9. https://pubmed.ncbi.nlm.nih.gov/11932310/
[13] Teichman SL, et al. [Adverse events.] J Clin Endocrinol Metab. 2006;91(3):799-805. https://pubmed.ncbi.nlm.nih.gov/16352683/
[16] U.S. FDA PCAC. Bulk drug substances for 503A — December 2024. FDA Docket FDA-2024-N-4777. https://www.fda.gov/media/183819/download
[18] Ionescu M, Frohman LA. [GH suppression absence.] J Clin Endocrinol Metab. 2006;91(12):4792-7. https://pubmed.ncbi.nlm.nih.gov/17018654/

---

A letterpress monograph on the GHRH analog CJC-1295 — with-DAC and without, hand-set from the peer-reviewed record, no clinic, no counter.